Literature DB >> 8625163

Papillary renal tumors. Morphologic, cytochemical, and genotypic features.

D J Lager1, B J Huston, T G Timmerman, S M Bonsib.   

Abstract

BACKGROUND: Papillary renal tumors lack alterations of chromosome 3 and show trisomy of chromosomes 7 and 17, genotypic features distinct from nonpapillary carcinomas.
METHODS: The authors examined 39 papillary renal neoplasms to identify morphologic features allowing distinction of high grade from low grade tumors. Twenty-nine papillary tumors and 13 nonpapillary tumors were examined for the presence of trisomy of chromosome 7 using fluorescence in situ hybridization. Data recorded included tumor size, stage, grade, architectural pattern, and the presence of glycogen, foam cells, and iron.
RESULTS: Nineteen tumors were classified as low grade and 20 as high grade. The high grade tumors more often formed tall papillae with solid and tubular areas and had more intracellular glycogen, whereas the low grade tumors were more often trabecular. There was no significant difference in tumor size or iron deposition. High grade tumors were of higher stage. Foam cells more commonly were noted in low grade tumors. Sixty-seven percent of low grade, 43% of high grade, and none of the nonpapillary tumors showed trisomy of chromosome 7. Metastases developed only in patients with high grade papillary tumors (10/19, 7 within 2 years of diagnosis), all of whom died of disease.
CONCLUSIONS: Papillary renal carcinomas with high nuclear grade are more likely to behave in an aggressive fashion, whereas those with low nuclear grade may be associated with longer disease free survival. Furthermore, trisomy of chromosome 7 can be identified by fluorescence in situ hybridization and is useful in differentiating true papillary from nonpapillary renal neoplasms.

Entities:  

Mesh:

Year:  1995        PMID: 8625163     DOI: 10.1002/1097-0142(19950815)76:4<669::aid-cncr2820760420>3.0.co;2-u

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  11 in total

1.  Papillary renal cell carcinoma. Prognostic value of morphological subtypes in a clinicopathologic study of 43 cases.

Authors:  Yves Allory; Delphine Ouazana; Eric Boucher; Nicolas Thiounn; Annick Vieillefond
Journal:  Virchows Arch       Date:  2003-04-04       Impact factor: 4.064

2.  Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes.

Authors:  Steffen Durinck; Eric W Stawiski; Andrea Pavía-Jiménez; Zora Modrusan; Payal Kapur; Bijay S Jaiswal; Na Zhang; Vanina Toffessi-Tcheuyap; Thong T Nguyen; Kanika Bajaj Pahuja; Ying-Jiun Chen; Sadia Saleem; Subhra Chaudhuri; Sherry Heldens; Marlena Jackson; Samuel Peña-Llopis; Joseph Guillory; Karen Toy; Connie Ha; Corissa J Harris; Eboni Holloman; Haley M Hill; Jeremy Stinson; Celina Sanchez Rivers; Vasantharajan Janakiraman; Weiru Wang; Lisa N Kinch; Nick V Grishin; Peter M Haverty; Bernard Chow; Julian S Gehring; Jens Reeder; Gregoire Pau; Thomas D Wu; Vitaly Margulis; Yair Lotan; Arthur Sagalowsky; Ivan Pedrosa; Frederic J de Sauvage; James Brugarolas; Somasekar Seshagiri
Journal:  Nat Genet       Date:  2014-11-17       Impact factor: 38.330

3.  Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.

Authors:  Toni K Choueiri; Ulka Vaishampayan; Jonathan E Rosenberg; Theodore F Logan; Andrea L Harzstark; Ronald M Bukowski; Brian I Rini; Sandy Srinivas; Mark N Stein; Laurel M Adams; Lone H Ottesen; Kevin H Laubscher; Laurie Sherman; David F McDermott; Naomi B Haas; Keith T Flaherty; Robert Ross; Peter Eisenberg; Paul S Meltzer; Maria J Merino; Donald P Bottaro; W Marston Linehan; Ramaprasad Srinivasan
Journal:  J Clin Oncol       Date:  2012-12-03       Impact factor: 44.544

4.  MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors.

Authors:  Denis L F Jardim; Débora de Melo Gagliato; Gerald Falchook; Ralph Zinner; Jennifer J Wheler; Filip Janku; Vivek Subbiah; Sarina A Piha-Paul; Siqing Fu; Nizar Tannir; Paul Corn; Chad Tang; Kenneth Hess; Sinchita Roy-Chowdhuri; Razelle Kurzrock; Funda Meric-Bernstam; David S Hong
Journal:  Clin Genitourin Cancer       Date:  2014-07-03       Impact factor: 2.872

Review 5.  Foretinib (XL880): c-MET inhibitor with activity in papillary renal cell cancer.

Authors:  Theodore F Logan
Journal:  Curr Oncol Rep       Date:  2013-04       Impact factor: 5.075

6.  Metanephric adenoma: the utility of immunohistochemical and cytogenetic analyses in differential diagnosis, including solid variant papillary renal cell carcinoma and epithelial-predominant nephroblastoma.

Authors:  Stephanie N Kinney; John N Eble; Ondrej Hes; Sean R Williamson; David J Grignon; Mingsheng Wang; Shaobo Zhang; Lee Ann Baldrige; Guido Martignoni; Matteo Brunelli; Lisha Wang; Eva Comperat; Rong Fan; Rodolfo Montironi; Gregory T MacLennan; Liang Cheng
Journal:  Mod Pathol       Date:  2015-08-07       Impact factor: 7.842

7.  Chromosomal imbalances in papillary renal cell carcinoma: genetic differences between histological subtypes.

Authors:  F Jiang; J Richter; P Schraml; L Bubendorf; T Gasser; G Sauter; M J Mihatsch; H Moch
Journal:  Am J Pathol       Date:  1998-11       Impact factor: 4.307

Review 8.  Metastatic non-clear cell renal cell carcinoma: an evidence based review of current treatment strategies.

Authors:  Alexander Sankin; A Ari Hakimi; James J Hsieh; Ana M Molina
Journal:  Front Oncol       Date:  2015-04-08       Impact factor: 6.244

9.  Comparison of chromosomal aberrations detected by fluorescence in situ hybridization with clinical parameters, DNA ploidy and Ki 67 expression in renal cell carcinoma.

Authors:  Y Wada; M Igawa; H Shiina; K Shigeno; H Yokogi; S Urakami; T Yoneda; R Maruyama
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

Review 10.  Genetic and Chromosomal Aberrations and Their Clinical Significance in Renal Neoplasms.

Authors:  Ning Yi Yap; Retnagowri Rajandram; Keng Lim Ng; Jayalakshmi Pailoor; Ahmad Fadzli; Glenda Carolyn Gobe
Journal:  Biomed Res Int       Date:  2015-09-13       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.